Aspen Neuroscience to Present at Future of Parkinson’s Disease Conference

SAN DIEGO and AUSTIN, Texas, Nov. 30, 2023 /PRNewswire/ — This week, Aspen Neuroscience will present to the Parkinson’s community at the Future of Parkinson’s Disease conference, held November 30 – December 3, in Austin. The joint annual conference is hosted by the Parkinson’s Foundation and the Parkinson Study Group. 

In addition to multiple scientific presentations, Aspen Chief Executive Officer Damien McDevitt, PhD, and co-founder and Senior Vice President of R&D, Andres Bratt-Leal, PhD, will present updates on company progress for upcoming Phase 1 clinical trials for ANPD001, a personalized (autologous) cell therapy under investigation to treat PD by replacing lost dopamine neurons. 

The Aspen Neuroscience schedule of presentations includes:

Presenter:  Andres Bratt-Leal, Ph.D.
Event:         Industry Forum Presentation for the Parkinson’s Study Group
Date:          Friday, December 1 
Time:         2:00pm – 3:30pm
Location:    Lonestar Ballroom E, 3rd Floor
Presenter:  Jeanne Drucks
Title:           Functional Characterization of GBA1 Mutations in iPSC-derived Midbrain Dopaminergic Neurons
Event:         Poster Reception
Date:          Friday, December 1 
Time:         5-7 p.m.
Location:    Griffin Hall
Presenter:  Roy Williams, Ph.D.
Title:           NeuriTest™: A bioinformatics-based tool for quality control of human iPSC-derived dopaminergic precursor cells
Event:         Poster Reception
Date:          Friday, December 1 
Time:         5-7 p.m.
Location:    Griffin Hall
Presenter:  Damien McDevitt, Ph.D.
Event:        Industry Science Presentation
Date:          Saturday, December 2 
Time:         7:30 a.m.
Location:    Room 201-202

About Aspen Neuroscience
Headquartered in San Diego, Aspen Neuroscience, Inc. is a clinical development-stage, private company focused on personalized (autologous) regenerative medicine. The company is developing patient-derived iPSCs to create personalized cell therapies that address diseases with high unmet medical needs, beginning with autologous neuron replacement for Parkinson’s disease and extending across the brain and affected organs.

A leading iPSC platform company, Aspen combines stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments. The company has developed a best-in-class platform to create and optimize iPSC-derived cell therapies, which includes in-house bioinformatics, manufacturing and QC. For more information and important updates, please visit

SOURCE Aspen Neuroscience, Inc.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.